Centre caps margins on 137 cancer drugs, prices may fall 70%
In short
The Centre has capped trade margins on 137 cancer drugs. The report says prices could drop by up to 70%, and the new prices will apply from 9 November.
This matters because patients may pay less for some cancer treatments. It is still not stated which exact brands are affected or how big the cut will be for each drug.
What the reporting says
The Centre has capped trade margins on 137 cancer drugs, and prices are likely to fall by up to 70%, according to the publisher-supplied summary. The NPPA’s new rules target markups of up to 700% in some cases, including widely used immunotherapies and targeted cancer treatments. Revised prices will take effect from 9 November. What remains unknown is the full list of affected brands and the final impact on patients and distributors.
Why it matters
The Centre has capped trade margins on 137 cancer drugs, with the publisher-supplied summary saying prices may fall by up to 70%. The NPPA’s new rules are said to target markups of up to 700% in some cases, including immunotherapies and targeted cancer treatments, and revised prices take effect from 9 November. The reporting does not identify every brand affected or the final patient impact.